| Literature DB >> 26380376 |
Ewelina Dziurkowska1, Marek Wesolowski1.
Abstract
Multivariate statistical analysis is widely used in medical studies as a profitable tool facilitating diagnosis of some diseases, for instance, cancer, allergy, pneumonia, or Alzheimer's and psychiatric diseases. Taking this in consideration, the aim of this study was to use two multivariate techniques, hierarchical cluster analysis (HCA) and principal component analysis (PCA), to disclose the relationship between the drugs used in the therapy of major depressive disorder and the salivary cortisol level and the period of hospitalization. The cortisol contents in saliva of depressed women were quantified by HPLC with UV detection day-to-day during the whole period of hospitalization. A data set with 16 variables (e.g., the patients' age, multiplicity and period of hospitalization, initial and final cortisol level, highest and lowest hormone level, mean contents, and medians) characterizing 97 subjects was used for HCA and PCA calculations. Multivariate statistical analysis reveals that various groups of antidepressants affect at the varying degree the salivary cortisol level. The SSRIs, SNRIs, and the polypragmasy reduce most effectively the hormone secretion. Thus, both unsupervised pattern recognition methods, HCA and PCA, can be used as complementary tools for interpretation of the results obtained by laboratory diagnostic methods.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26380376 PMCID: PMC4562094 DOI: 10.1155/2015/987435
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Average levels of cortisol in saliva of patients under antidepressant therapy.
| Antidepressant | Active substance | Monotherapy | Polypragmasy | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | Mean concentration of salivary cortisol, ng/mL | Number of patients | Mean concentration of salivary cortisol, ng/mL | ||||||||
| Initial | Final | Highest | Lowest | Initial | Final | Highest | Lowest | ||||
| TCAs | Amitriptyline (100 mg) | 7 | 53.03 | 18.84 | 161.25 | 1.25 | — | ||||
| Clomipramine (100 mg) | 3 | 16.46 | 13.08 | 55.00 | 2.50 | 1 | 72.00 | 5.50 | 72.00 | 2.62 | |
| Opipramol (100 mg) | 1 | 33.75 | 13.75 | 33.75 | 2.50 | — | |||||
| Doxepin (100 mg) | 1 | 87.72 | 5.62 | 87.72 | 1.62 | 1 | 13.50 | 2.00 | 13.50 | 2.00 | |
|
| |||||||||||
| SSRIs | Sertraline (50 mg) | 10 | 39.44 | 32.51 | 190.00 | 0.25 | 5 | 39.60 | 5.10 | 95.00 | 1.25 |
| Citalopram (40 mg) | 7 | 59.46 | 6.89 | 93.25 | 0.62 | 3 | 52.42 | 8.42 | 72.00 | 1.75 | |
| Escitalopram (20 mg) | 5 | 47.46 | 4.77 | 98.50 | 1.25 | 4 | 39.45 | 5.06 | 61.00 | 1.25 | |
| Fluvoxamine (100 mg) | 3 | 43.54 | 20.75 | 49.75 | 2.50 | — | |||||
| Fluoxetine (20 mg) | 1 | 2.50 | 3.75 | 3.75 | 2.50 | — | |||||
| Paroxetine (20 mg) | 2 | 68.25 | 98.94 | 195.00 | 2.50 | — | |||||
|
| |||||||||||
| SNRIs | Venlafaxine (75 mg) | 14 | 88.32 | 9.13 | 372.5 | 0.25 | 5 | 41.55 | 5.45 | 95.00 | 2.50 |
| SSAs | Mianserin (90 mg) | 7 | 63.75 | 26.05 | 195.00 | 1.25 | 5 | 33.27 | 6.90 | 46.25 | 1.25 |
| NaSSAs | Mirtazapine (45 mg) | 1 | 33.00 | 8.62 | 33.00 | 6.25 | 1 | 31.25 | 2.75 | 31.25 | 2.50 |
| SARIs | Trazodone (300 mg) | 3 | 79.17 | 6.46 | 182.50 | 1.25 | 8 | 32.91 | 4.03 | 45.75 | 1.50 |
| SSREs | Tianeptine (37.5 mg) | 3 | 40.50 | 16.62 | 52.00 | 1.75 | — | ||||
| RIMA | Moclobemid (600 mg) | 1 | 37.50 | 5.62 | 37.50 | 1.25 | — | ||||
| Others psychoactive drugs | 10 | 44.51 | 12.22 | 133.50 | 1.25 | 1 | 42.50 | 25.00 | 42.50 | 2.50 | |
TCAs: tricyclic antidepressants, SSRIs: selective serotonin reuptake inhibitors, SNRIs: serotonin-noradrenalin reuptake inhibitors, SSAs: specific serotonin antidepressants, NaSSAs: noradrenergic and selective serotoninergic antidepressants, SARIs: serotonin antagonist and reuptake inhibitors, SSREs: selective serotonin reuptake enhancers, and RIMA: reversible inhibitors of monoaminooxidase-A.
Figure 1HCA dendrogram illustrating the clustering of ninety seven patients under antidepressant therapy.
Characteristic features of four groups of patients under antidepressant therapy displayed by HCA dendrogram.
| HCA cluster | Antidepressant | Number of patients | Age of patients, years | Multiplicity of hospitalization | Hospitalization period, days | Initial and final cortisol levels, ng/mL | Highest and lowest cortisol levels, ng/mL | Mean cortisol level, ng/mL | Median for cortisol level, ng/mL |
|---|---|---|---|---|---|---|---|---|---|
| Cluster Ia | TCAs | 5 | 51 | 3 | 29 | 16.57–9.67 | 1.25–26.25 | 10.80 | 8.44 |
| SSRIs | 9 | 49 | 2 | 63 | 17.33–4.83 | 2.00–31.50 | 8.51 | 6.94 | |
| SNRIs | 2 | 44 | 1 | 59 | 15.00–5.53 | 1.25–24.75 | 8.50 | 7.53 | |
| SSAs | 3 | 39 | 2 | 66 | 20.58–5.21 | 1.25–24.25 | 9.30 | 8.75 | |
| NaSSAs | 1 | 63 | 1 | 21 | 33.00–8.62 | 6.25–33.00 | 17.50 | 8.62 | |
| SSREs | 1 | 28 | 7 | 46 | 27.50–9.25 | 1.75–27.50 | 8.62 | 7.62 | |
| Others psychoactive drugs | 4 | 44 | 3 | 25 | 12.56–7.92 | 1.37–21.25 | 7.59 | 6.69 | |
| Polypragmasy | 3 | 50 | 2 | 40 | 11.79–2.42 | 1.25–15.62 | 5.48 | 6.00 | |
|
| |||||||||
| Cluster Ib | TCAs | 4 | 55 | 1 | 71 | 31.06–11.59 | 1.25–55.00 | 12.98 | 9.15 |
| SSRIs | 7 | 46 | 2 | 48 | 32.99–11.05 | 1.25–49.75 | 11.78 | 7.50 | |
| SNRIs | 5 | 45 | 2 | 63 | 33.80–12.57 | 1.25–62.50 | 9.31 | 4.00 | |
| SSAs | 1 | 57 | 2 | 46 | 29.50–2.87 | 1.25–29.50 | 6.34 | 4.62 | |
| SARIs | 2 | 42 | 5 | 80 | 27.50–7.19 | 1.25–37.50 | 9.13 | 7.34 | |
| SSREs | 2 | 47 | 2 | 21 | 47.00–20.31 | 1.75–52.00 | 16.24 | 10.69 | |
| RIMA | 1 | 50 | 5 | 23 | 37.50–5.62 | 1.25–37.50 | 10.41 | 6.12 | |
| Others psychoactive drugs | 4 | 42 | 3 | 31 | 34.75–7.70 | 1.25–38.75 | 11.84 | 6.25 | |
| Polypragmasy | 9 | 48 | 3 | 39 | 38.46–5.10 | 1.25–46.25 | 9.15 | 7.53 | |
|
| |||||||||
| Cluster II | TCAs | 2 | 60 | 1 | 28 | 86.86–6.62 | 1.62–87.70 | 22.26 | 10.53 |
| SSRIs | 6 | 49 | 3 | 46 | 77.59–15.71 | 1.25–95.00 | 14.19 | 7.62 | |
| SNRIs | 5 | 45 | 1 | 38 | 82.25–7.85 | 2.50–91.00 | 20.97 | 10.00 | |
| SSAs | 2 | 58 | 1 | 53 | 58.00–6.31 | 1.37–102.00 | 12.47 | 7.87 | |
| Polypragmasy | 2 | 62 | 5 | 45 | 76.00–9.54 | 2.50–95.00 | 20.62 | 8.34 | |
|
| |||||||||
| Cluster III | TCAs | 1 | 31 | 3 | 32 | 161.25–83.75 | 8.75–161.25 | 50.57 | 30.62 |
| SSRIs | 4 | 48 | 3 | 35 | 87.44–105.00 | 0.25–195.00 | 19.55 | 9.06 | |
| SNRIs | 3 | 44 | 2 | 51 | 234.96–7.72 | 0.25–3.75 | 30.03 | 5.94 | |
| SSAs | 1 | 53 | 6 | 29 | 195.00–151.25 | 5.00–195.00 | 26.03 | 11.25 | |
| SARIs | 1 | 51 | 4 | 76 | 182.50–5.00 | 1.25–182.50 | 26.73 | 13.00 | |
| Others psychoactive drugs | 2 | 45 | 2 | 33 | 366.27–41.25 | 1.25–133.50 | 16.97 | 7.28 | |
Figure 2PCA scores plot illustrating the grouping of ninety-seven patients under antidepressant therapy. ○: cluster Ia, ●: cluster Ib, □: cluster II, and ■: cluster III.
Figure 3PCA loadings plot illustrating the impact of fourteen raw variables on the scattering of ninety-seven patients under antidepressant therapy. The Arabic digits denote the raw variables as follows: 1: patients age, 2: multiplicity of hospitalization, 3: period of hospitalization, 4: initial cortisol level, 5: final cortisol level, 6: the highest cortisol concentration, 7: the lowest cortisol concentration, 8: difference between the highest and lowest cortisol concentration, 9: mean concentration, 10: median determined during the whole period of hospitalization, 11: mean level of hormone during the 30% of the hospitalization period, 12: mean level of hormone during the 60% of the hospitalization period, 13: mean level of hormone during the 90% of the hospitalization period, 14: standard deviation of the mean concentration, 15: relative standard deviation of the mean concentration, and 16: antidepressant.